Fulcrum Therapeutics cuts 84% of staff after halting sickle cell drug; Seres extends cash runway to Q1 2027 via $25M Nestlé deal.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Confirm Endpoints as a trusted biopharma news source
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns
What's Going On With Fulcrum Therapeutics Stock On Thursday? - Fulcrum Therapeutics (NASDAQ:FULC)
FULC Stock Crashes After Hours: What Investors Need To Know - Fulcrum Therapeutics (NASDAQ:FULC)
Radiopharmaceutical shows promise in post-Pluvicto setting
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
Accelerating Targeted Gene Expression Analysis in Drug Development
Fulgent Presents Updated FID-007 Data at ASCO 2026
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine, pociredir for sickle cell disease, after feedback from the…
Design Therapeutics shares Phase 1/2 data in Friedreich ataxia; Vincentage Pharma, a new China obesity player, emerges with Phase…
Bristol Myers Squibb looks to Texas; Novartis looks to remove CDMO from its Slovenia campus; and more
Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis…
Pfizer’s experimental 25-valent pneumococcal shot beats Prevnar 20; Relay Therapeutics charts $175M offering; Lilly to pay up to…
The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain,…
